Bluyssen HA - Search Results

1

In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.

Szelag M, Sikorski K, Czerwoniec A, Szatkowska K, Wesoly J, Bluyssen HA. Szelag M, et al. Among authors: bluyssen ha. Eur J Pharmacol. 2013 Nov 15;720(1-3):38-48. doi: 10.1016/j.ejphar.2013.10.055. Epub 2013 Nov 6. Eur J Pharmacol. 2013. PMID: 24211327

2

STAT1-mediated signal integration between IFNγ and LPS leads to increased EC and SMC activation and monocyte adhesion.

Sikorski K, Chmielewski S, Przybyl L, Heemann U, Wesoly J, Baumann M, Bluyssen HA. Sikorski K, et al. Among authors: bluyssen ha. Am J Physiol Cell Physiol. 2011 Jun;300(6):C1337-44. doi: 10.1152/ajpcell.00276.2010. Epub 2011 Feb 23. Am J Physiol Cell Physiol. 2011. PMID: 21346151 Free article.

3

STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease.

Sikorski K, Czerwoniec A, Bujnicki JM, Wesoly J, Bluyssen HA. Sikorski K, et al. Among authors: bluyssen ha. Cytokine Growth Factor Rev. 2011 Aug;22(4):211-9. doi: 10.1016/j.cytogfr.2011.06.003. Epub 2011 Jul 12. Cytokine Growth Factor Rev. 2011. PMID: 21752694 Review.

4

Comparative screening and validation as a novel tool to identify STAT-specific inhibitors.

Szeląg M, Czerwoniec A, Wesoly J, Bluyssen HA. Szeląg M, et al. Among authors: bluyssen ha. Eur J Pharmacol. 2014 Oct 5;740:417-20. doi: 10.1016/j.ejphar.2014.05.047. Epub 2014 Jun 2. Eur J Pharmacol. 2014. PMID: 25183399

5

Data mining of atherosclerotic plaque transcriptomes predicts STAT1-dependent inflammatory signal integration in vascular disease.

Sikorski K, Wesoly J, Bluyssen HA. Sikorski K, et al. Among authors: bluyssen ha. Int J Mol Sci. 2014 Aug 18;15(8):14313-31. doi: 10.3390/ijms150814313. Int J Mol Sci. 2014. PMID: 25196434 Free PMC article.

6

Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.

Szelag M, Czerwoniec A, Wesoly J, Bluyssen HA. Szelag M, et al. Among authors: bluyssen ha. PLoS One. 2015 Feb 24;10(2):e0116688. doi: 10.1371/journal.pone.0116688. eCollection 2015. PLoS One. 2015. PMID: 25710482 Free PMC article.

7

STAT1 as a central mediator of IFNγ and TLR4 signal integration in vascular dysfunction.

Sikorski K, Chmielewski S, Olejnik A, Wesoly JZ, Heemann U, Baumann M, Bluyssen H. Sikorski K, et al. JAKSTAT. 2012 Oct 1;1(4):241-9. doi: 10.4161/jkst.22469. JAKSTAT. 2012. PMID: 24058779 Free PMC article. Review.

8

STAT1-dependent signal integration between IFNγ and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis.

Chmielewski S, Olejnik A, Sikorski K, Pelisek J, Błaszczyk K, Aoqui C, Nowicka H, Zernecke A, Heemann U, Wesoly J, Baumann M, Bluyssen HA. Chmielewski S, et al. Among authors: bluyssen ha. PLoS One. 2014 Dec 5;9(12):e113318. doi: 10.1371/journal.pone.0113318. eCollection 2014. PLoS One. 2014. PMID: 25478796 Free PMC article.

9

STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1.

Blaszczyk K, Olejnik A, Nowicka H, Ozgyin L, Chen YL, Chmielewski S, Kostyrko K, Wesoly J, Balint BL, Lee CK, Bluyssen HA. Blaszczyk K, et al. Among authors: bluyssen ha. Biochem J. 2015 Mar 15;466(3):511-24. doi: 10.1042/BJ20140644. Biochem J. 2015. PMID: 25564224 Free PMC article.

10

Advances in peptidic and peptidomimetic-based approaches to inhibit STAT signaling in human diseases.

Szelag M, Wesoly J, Bluyssen HA. Szelag M, et al. Among authors: bluyssen ha. Curr Protein Pept Sci. 2016;17(2):135-46. doi: 10.2174/1389203716666151102103706. Curr Protein Pept Sci. 2016. PMID: 26521960 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

66 results

Search Page